gutflix
GI learning, personalised

Summary

CAR T cells: A new treatment option

Raja Atreya

UEG Week Barcelona 2026 | Presentation

Immunology | Mechanisms & Personalised Medicine | IBD

October 19, 2026

A single multi-refractory ulcerative colitis patient achieved 18-month drug-free remission following CD19 CAR-T cell therapy, with the speaker reporting early mucosal immune remodeling across multiple cell lineages and suppression of alpha-v-beta-6 autoantibodies.

KEY POINTS

- The speaker reported clinical remission within 10 days and endoscopic/histological remission by 2 months in a 21-year-old patient refractory to infliximab, upadacitinib, and cyclosporin who refused colectomy
- Drug-free clinical remission persisted at 18 months with the last endoscopy at month 12 showing endoscopic and histological remission, according to the speaker
- Serial single-cell sequencing showed depletion of CD19-positive plasma cells, expansion of non-cytotoxic CD8-positive tissue-resident memory T cells, shift from M1 to M2 macrophages, rise in Best4-positive enterocytes and goblet cells, and fibroblast remodeling
- Suppression of alpha-v-beta-6 autoantibody production persisted after peripheral B cell re-emergence at day 239, as stated by the speaker
- The speaker emphasized this is a single investigator-initiated case report requiring controlled studies before defining which patients qualify for therapy

VIEW THIS CONTENT ON GUTFLIX

https://gutflix.eu/search/d/241441bc-d150-11f1-8886-daaa6dbee0a2

AI-generated summary

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.